Skip to main content
Caplight Logo









INViCARE

INViCARE

Private
MontrealHealthcare & Life Scienceshttp://invicare.ca/

Last Round

Grant

Apr 5, 2018

Total Funding Raised

$5,000

Momentum

Top 50%

of companies Caplight tracks

Company Overview

INViCARE operates in Healthcare & Life Sciences and is based in Montreal. Its latest recorded funding round was a Grant round in April 2018.

INViCARE is a biotechnology company that develops nanocrystalline biomaterials designed to prevent and treat dental implant infections.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

INViCARE Comparables

Compare INViCARE with similar companies based on industry and business-model similarity.

INViCARE comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Regedent AG
83%
RLS Global AB
79%
Prudentix Ltd.
78%
Book a demo to see all comparables

For institutional investors. Book with your work email.

INViCARE Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantApr 5, 2018
GrantJun 8, 2017
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

INViCARE Investors

Notable investors and investment history

INViCARE investors
InvestorRounds
MitacsGrant
CentechAccelerator
McGill Dobson Centre for EntrepreneurshipGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 24, 2026

    Monthly visitors grew 79% MoM, from 258 to 461.

  • Jun 8, 2017

    $5K grant received from Mitacs

Book a demo to see all signals

For institutional investors. Book with your work email.

INViCARE Filings

Explore SEC and related filing metadata, where available.

INViCARE filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about INViCARE's valuation, stock price, and market status.

Is INViCARE a public or private company?

INViCARE is a private company.

What is the current stock price of INViCARE?

INViCARE is a private company, so its shares have no public market price. Caplight tracks INViCARE's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is INViCARE worth (valuation)?

Valuation information for INViCARE is not publicly available.

Can I buy INViCARE stock?

INViCARE shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was INViCARE's last funding round?

INViCARE's most recent funding round was Grant on April 5, 2018.

Who are the main investors in INViCARE?

Key investors in INViCARE include Mitacs, Centech, McGill Dobson Centre for Entrepreneurship.

Will INViCARE IPO soon?

No public IPO plans have been announced for INViCARE.

How can I track INViCARE secondary market activity?

Caplight tracks bids, offers, and trades in INViCARE's shares on secondary markets.

Firmographic Details

HeadquartersMontreal
Employee Range1
Year Founded2017
Last FundingApr 5, 2018

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?